ftInvstr
MARKSANS · Healthcare ₹308.95 +1.71% Mkt Cap ₹14019 Cr overvalued
← Search another stock

MARKSANS

Healthcare Drug Manufacturers - General
★ Watchlist ⧉ Add to bucket
₹308.95
+1.71% today · 30d +0.08%
as of 2026-11-09
Price · Daily Candles
AI narrative is temporarily unavailable for MARKSANS. The deterministic sections below render from live data.
₹ Latest Earnings · Q ending 2026-09-30
REVENUE
₹940 Cr
+30.5% YoY
NET PROFIT
₹144 Cr
+44.77% YoY
OPM
24.25%
+1.87pp YoY
EPS
₹3.12
PE 24.82
Intrinsic value · DCF ₹78.64 · Margin of safety -74.5% (overvalued) · FCF yield 2.34%
◇ Sector Position
PEERPEROCE %
MARKSANS24.8220.0
GLAXO40.0557.97
RUBICON90.2127.36
PFIZER20.9324.29
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
79
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 100
Valuation REASONABLE 60
Growth STRONG 88
Profitability HIGH 85
Technicals NEUTRAL 62
Risk LOW 80
Key Stats
TTM PE
24.82
P/B
4.17
52W HIGH
₹350.95
OFF HIGH
-11.97%
DIV YIELD
0.29%
MKT CAP
₹14019 Cr
◉ Active Signals
MACDNeutral0.8808
RSI(14)Neutral49.53
Street Consensus
3 analysts
₹322.33
mean target
Low ₹210.0Now ₹308.95High ₹385.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold MARKSANS and at what entry.

Sign up freeSign in
AI-generated research based on publicly available data and ftInvstr's bias-safe quantitative models. Not investment advice. Past performance does not guarantee future results. Consult a SEBI-registered investment adviser before making any investment decision.